3Outen I, Cangir A K, Ozdemir N, et al. Management of esophageal perforation [ J ]. Surg Today,2001,32 ( 1 ) :76.
4Ferri L, Lee J K, Law S, et al. Management of spontaneous perforation of esophageal cancer with covered self expanding metallic stents [ J]. Dis Esophagus,2005,18( 1 ) :67.
5Salo J A, Isolauri J O, Heikkils L J, et al. Management of delayed esophageal perforation with mediastinal sepsis [ J]. Jthorac Cardiovasc Surg, 1993,106 (6) : 1088.
7Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 8501). Radiation Therapy Oncology Group [J]. JAMA, 1999,281 (17) : 1623- 1627.
8Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with Docetaxel and Cisplatin in squamous esophageal carcinoma [ J ]. Dis Esophagus, 2010,23 (3) : 253- 259.
9Ruppert BN, Watkins JM, Shirai K, et al. Cisplatin/lrinotecan versus Carboplatin/Paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer [J]. Am J Clin Oncol, 2010,33(4) :346-352.
10Conroy T, Yataghene Y, Etinne PL, et al. Phase lI randomized trial of chemoradiotherapy with FOLFOX4 or Cisplatin plus Fluorouraeil in esophageal cancer[J]. Br J Cancer, 2010, 103 (9) : 1349-1355.
